CSL Shares Marginally Higher on Influenza Vaccine Study Data

MT Newswires Live

2025/10/22

CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.

Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.

A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.

A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577438714"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577438714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577438714?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577438714","market":"hk","top_or_hot":-1,"title":"CSL Shares Marginally Higher on Influenza Vaccine Study Data","media":"MT Newswires Live","content":"<html><body><p> CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.</p><p>Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.</p><p>A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.</p><p>A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Shares Marginally Higher on Influenza Vaccine Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Shares Marginally Higher on Influenza Vaccine Study Data\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-22 09:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.</p><p>Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.</p><p>A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.</p><p>A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577438714","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577438714","pubTimestamp":1761097234,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL's  shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines  and high-dose quadrivalent influenza vaccines  was comparable across all settings.Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","CSL":"卡莱尔伙伴","BK4086":"建筑产品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL.AU":"CSL LIMITED","BK7067":"生物科技","BK7511":"ESG概念","BK7501":"新冠治疗股"},"translate_title":"CSL股价因流感疫苗研究数据小幅走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5},"content_text":"CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}